NYSE:AORTMedical Equipment
Is Artivion's Upgraded Outlook and Trial Launch Reshaping the Investment Case for AORT?
Artivion, Inc. recently reported strong third-quarter results, with revenue rising to US$113.39 million and turning to a net income of US$6.5 million compared to a net loss a year earlier, while also raising its full-year 2025 revenue and EBITDA guidance.
This momentum was further supported by the initiation of the pivotal ARTIZEN trial for the Arcevo LSA stent graft system, signaling ongoing innovation and expansion in the aortic arch repair segment.
We’ll examine how the raised full-year...